

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**3DMed**

**思路迪**

**3D Medicines Inc.**

**思路迪医药股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1244)**

## **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2023 ANNUAL REPORT**

Reference is made to (i) the prospectus (the “**Prospectus**”) issued by 3D Medicines Inc. (the “**Company**”) dated November 29, 2022 in relation to the listing of the Company’s ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited on December 15, 2022 (the “**Listing**”); and (ii) the annual report for the year ended December 31, 2023 (the “**2023 Annual Report**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as used in the Prospectus and the 2023 Annual Report.

### **USE OF PROCEEDS**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to provide the shareholders of the Company and potential investors with the following additional information pursuant to paragraph 11(8) and 11A of Appendix D2 of the Listing Rules in relation to (i) the details of the net proceeds from the Global Offering and the purposes for which they are used in the year ended December 31, 2023; and (ii) whether the proceeds from the 2023 Placing has been and will be used according to the intentions previously disclosed by the Company.

## USE OF PROCEEDS FROM THE GLOBAL OFFERING

An analysis of the Use of Proceeds from the Global Offering as at the year ended December 31, 2023 are set out below:

Intended use of proceeds as stated in the Prospectus	Percentage to total amount %	Total net proceeds from the Global Offering (including the proceeds from the partial exercise of the Over-allotment Option) (RMB'000)	Utilised amount during the period from January 1, 2023 to December 31, 2023 (RMB'000)	Utilised	Unutilised	Expected timeline for unutilized amount
				amount as at December 31, 2023 (RMB'000)	amount as at December 31, 2023 (RMB'000)	
(a) Research and development, regulatory filings and commercialization of our product and drug candidates:	90	209,635.1	85,939.5	97,842.4	111,792.7	Dec, 2025
(i) 恩維達® envafolimab	55	128,110.3	45,058.4	56,337.4	71,773.0	Dec, 2025
(ii) other drug candidates	25	58,232.0	37,516.0	38,139.8	20,092.1	Dec, 2025
(iii) the construction of our in-house production facilities in Xuzhou, Jiangsu province and procurement of new machineries, instruments and equipment	10	23,292.8	3,365.2	3,365.2	19,927.6	Dec, 2025
(b) General corporate and working capital purposes	10	23,292.8	21,992.4	23,292.8	–	N/A
<b>Total</b>	<b>100</b>	<b>232,927.9</b>	<b>107,931.8</b>	<b>121,135.1</b>	<b>111,792.8</b>	

## **USE OF PROCEEDS FROM THE 2023 PLACING**

The Group will utilize the Net Proceeds in accordance with the intended purposes as set out in the announcement of the Company dated July 14, 2023. The Board is not aware of any material change to the planned use of the Net Proceeds as at the date of the 2023 Annual Report.

The Board also confirmed that the supplemental information provided in this announcement does not affect any other information contained in the 2023 Annual Report.

By order of the Board  
**3D Medicines Inc.**  
**Dr. Gong Zhaolong**  
*Chairman of the Board*

Hong Kong, September 4, 2024

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.*